USMLE Prep - Medical Reference Library

Male Hypogonadism — Workup & Treatment

System: Endocrinology • Reviewed: Aug 31, 2025 • Step 1Step 2Step 3

Synopsis:

Confirm low morning testosterone on two occasions with symptoms; differentiate primary vs secondary; treat with testosterone when indicated while addressing fertility and contraindications.

Key Points

  • Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
  • Use system-specific risk tools to guide testing and disposition.
  • Order high-yield tests first; escalate imaging when indicated.
  • Start evidence-based initial therapy and reassess frequently.

Algorithm

  1. Primary survey and vitals; IV access and monitors.
  2. Focused history/physical; identify red flags and likely etiologies.
  3. Order system-appropriate labs and imaging (see Investigations).
  4. Initiate guideline-based empiric therapy (see Pharmacology).
  5. Reassess response; arrange consultation and definitive management.

Clinical Synopsis & Reasoning

For Male Hypogonadism Workup Treatment, frame the differential by acuity and pathophysiology, then align diagnostics to the leading hypotheses. Prioritize stabilization while obtaining high‑yield studies such as BMP (Electrolytes/anion gap), Ketones (if DKA) (Ketoacidosis), ABG/VBG (Acid–base status). Incorporate bedside imaging and targeted labs to define severity and identify complications; synthesize results with clinical trajectory to refine the working diagnosis and disposition needs.


Treatment Strategy & Disposition

Initiate disease‑directed therapy alongside supportive care, titrating to objective response. Pharmacologic options commonly include Insulin, Dextrose, Electrolytes (K+, Mg2+). Use validated frameworks (e.g., Monitoring on TRT) to guide escalation and site of care. Address precipitating factors, de‑escalate empiric therapies with data, and arrange follow‑up for monitoring and risk‑factor modification; admit patients with instability, high risk of deterioration, or needs for close monitoring.


Management Notes

Avoid TRT in men seeking fertility—consider clomiphene or hCG. Use shared decision-making for CV risk.


Epidemiology / Risk Factors

  • Diabetes and endocrine disorders depending on topic

Investigations

TestRole / RationaleTypical FindingsNotes
BMPElectrolytes/anion gapDerangements
Ketones (if DKA)KetoacidosisPositive
ABG/VBGAcid–base statusAcidosis/alkalosis

Monitoring on TRT

ParameterWhen
HematocritBaseline, 3–6 mo, then annually (hold if >54%)
PSA/DRE (men >40–50)Baseline and per screening guidance
Testosterone level2–3 months after initiation/titration
Lipids/A1cAs clinically indicated
Sleep apnea/LUTSReassess symptoms

Pharmacology

MedicationMechanismOnsetRole in TherapyLimitations
AcetaminophenAnalgesic/antipyreticHoursSymptom control as appropriateHepatotoxicity (overdose)
Ondansetron5-HT3 antagonismMinutesAntiemesis if neededQT prolongation

Prognosis / Complications

  • Improves with derangement correction; recurrence if triggers persist

Patient Education / Counseling

  • Explain red flags and when to seek emergent care.
  • Reinforce medication adherence and follow-up plan.

References

  1. Endocrine Society — Testosterone Therapy — Link